Bone Care International Announces Appointment of Paul L. Berns as President and CEO.

Business Editors/Health & Medical Writers

MIDDLETON, Wis.--(BUSINESS WIRE)--June 5, 2002

Bone Care International, Inc. (NASDAQ: BCII), announced today that Paul L. Berns will become President and CEO as of 10 June 2002, and also will join the Board of Directors. Mr. Berns was formerly Vice President and General Manager of the Immunology and Oncology business unit of Abbott Laboratories. His prior appointments included ten years at Bristol Myers Squibb, where he became the Vice President of Neuroscience Marketing, and more recently Vice President of Marketing at BASF Pharmaceuticals prior to its acquisition by Abbott. The retained search for the position was conducted by the health care group of TMP Worldwide.

Dr. Richard B. Mazess, Chairman and Acting President, indicated that "the Board was extremely pleased to have been able to recruit an extremely talented individual whose demonstrated sales and marketing skills will aid Bone Care as it transitions from a research endeavor to a fully functional pharmaceutical enterprise." Dr. Mazess, who founded the company, will remain Chairman of the Board, and will stay closely affiliated with the company to provide guidance on patents, basic research, and clinical development.

Bone Care is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon.

This press release contains forward-looking statements. Statements relating to future net sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, technical risks associated with the development of new products, regulatory policies in the United States and other countries, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company's operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.